We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Methylated DNA Profiling Explored for Prenatal Testing Applications

By LabMedica International staff writers
Posted on 17 Nov 2020
A method for analyzing cell-free methylated DNA being developed for use in cancer liquid biopsy testing can potentially also be used for prenatal testing applications. More...


The method called, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), uses antibodies to pull out small quantities of methylated, circulating, cell-free DNA. The method avoids the chemical conversion and destructive nature of bisulfite sequencing, the gold-standard method for methylation profiling.

A team of scientists at Princess Margaret Cancer Centre (Toronto, ON, Canada) presented data on cfDNA from three maternal plasma samples taken between weeks 17 and 18 of gestation. Using principal component analysis, The team was able to separate placental from non-placental DNA, based on known placenta methylome regulators, including tumor suppressors, transposon silencing elements, and placenta imprinted regions. The team is in the process of collecting 300 patient samples representing preterm births and healthy controls.

Using cfMeDIP-seq and machine learning, the team hope to be able to predict subtypes of preterm birth, as well as early and late preeclampsia. In addition, using synthetic spike-in controls with unique molecular indices, the investigators were able to use generalized linear models to absolutely quantify cfDNA, allowing them to correct for enrichment and sequencing biases associated with fragment length, GC content, and CpG dinucleotide fraction within a fragment.

Samantha L. Wilson, PhD, a medical geneticist and the first author of the study, said., “In this study, we have looked at the chemical changes found between circulating DNA of healthy pregnancies and pregnancies involving premature birth. We have identified changes in DNA methylation that can determine pregnancies with a high risk of premature birth. Since the test only uses DNA in the mother's blood, we can do this with a noninvasive blood test with little additional risk to the pregnancy. This study resulted in a noninvasive blood test that can detect pregnancies with increased risk of premature delivery. Use of this test will lead to changes in pregnancy care to try to prevent premature birth.”

Dr. Wilson, added “Currently we're sequencing everything, and it's expensive. If we find a machine learning model that is able to predict preterm birth or whatever pregnancy complication we're looking at, the next step is to reduce the dimensions in the data and create a panel that would be more cost effective for a healthcare setting.” The study was presented at the American Society of Human Genetics 2020 virtual conference, held October 27-30, 2020.

Related Links:
Princess Margaret Cancer Centre


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.